proposal
- India
DCGI approves Phase II/III clinical trial of COVAXIN in the age group of 2 to 18 Years
The National Regulator of the country, the Drugs Controller General of India (DCGI), after careful examination, has accepted the recommendation…
Read More » - Technology
DXC Technology Statement
Tysons, Va., United States: As previously announced, on January 6, 2021, DXC Technology (NYSE: DXC) (“DXC”) received an unsolicited, preliminary and non-binding…
Read More »